Japanese Pharmacology & Therapeutics（JPT）
Vol. 28 Suppl. 1 2000
Phase I clinical study of paroxetine HCl（Study 1）
－Safety and clinical pharmacological profile after single and 10-day once daily repeat oral administration of paroxetine HCl 20 mg to healthy adult male volunteers－
M. Murasaki, et al.
Jpn Pharmacol Ther 2000 28(S1) 7
Phase I clinical study of paroxetine HCl（Study 2）
－Pharmacokinetics after single and 10-day once daily repeat oral administration of paroxetine HCl 20 mg
to healthy adult male volunteers－
M. Murasaki, et al.
Jpn Pharmacol Ther 2000 28(S1) 37
Phase I clinical study of paroxetine HCl（Study 3）
－Pharmacokinetics after single oral administration of paroxetine HCl
10, 20 and 40 mg to healthy adult male volunteers－
H. Irie, et al.
Jpn Pharmacol Ther 2000 28(S1) 47
Phase I clinical study of paroxetine HCl（Study 4）
－Safety after single oral administration of paroxetine HCl 40 mg
to healthy adult male volunteers－
H. Irie, et al.
Jpn Pharmacol Ther 2000 28(S1) 69-
Phase I clinical study of paroxetine HCl（Study 5）
－Pharmacokinetics and safety after single oral administration of paroxetine HCl 20 mg to healthy elderly volunteers－
R. Nagata, et al.
Jpn Pharmacol Ther 2000 28(S1) 89
Phase I clinical study of paroxetine HCl（Study 6）
－Lack of ethnic difference in pharmacokinetics of paroxetine in healthy adults－
T. Sakamoto, et al.
Jpn Pharmacol Ther 2000 28(S1) 111
Early phase II study of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of depression and depressive episodes
S. Miura, et al.
Jpn Pharmacol Ther 2000 28(S1) 119
Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of depression or depressive episodes
－Dose ranging study with imipramine HCl－
S. Miura, et al.
Jpn Pharmacol Ther 2000 28(S1) 137
Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of depression or depressive episodes
－Double-blind, parallel group study with trazodone HCl－
S. Tsutsui, et al.
Jpn Pharmacol Ther 2000 28(S1) 161
Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of depression or depressive episodes
－Double-blind, parallel group study with amitriptyline HCl－
S. Miura, et al.
Jpn Pharmacol Ther 2000 28(S1) 187
Long-term treatment study of paroxetine HCl, a selective serotonin reuptake inhibitor in the treatment of depression or depressive episodes
T. Kinoshita, et al.
Jpn Pharmacol Ther 2000 28(S1) 211
Study of paroxetine HCl, a selective serotonin reuptake inhibitor, in elderly patients with depression or depressive episodes
N. Kataoka, et al.
Jpn Pharmacol Ther 2000 28(S1) 225
Pharmacokinetic study of paroxetine HCl, a selective serotonin reuptake inhibitor, in depressed patients with hepatic or renal impairment
K. Kobayashi, et al.
Jpn Pharmacol Ther 2000 28(S1) 237
Early phase II study of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder
S. Tsutsui, et al.
Jpn Pharmacol Ther 2000 28(S1) 253
Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder
－Late phase II double-blind, parallel group study－
S. Tsutsui, et al.
Jpn Pharmacol Ther 2000 28(S1) 271
Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder
－Phase III double-blind, parallel group study－
S. Tsutsui, et al.
Jpn Pharmacol Ther 2000 28(S1) 295